In an expression analysis effort of adult B-ALL patients, survivin was the only LAA that was identified to be significantly overexpressed in these patients compared to healthy donor samples, suggesting survivin as an excellent target antigen for immunotherapy in adult B-ALL patients [145]. Here, BIRC5 is linked to precursor B-cell acute lymphoblastic leukemia.